{
  "extraction_metadata": {
    "timestamp": "2025-09-05T13:51:26.488119",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 3,
    "total_picos": 19
  },
  "picos_by_country": {
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, 10.6 months for sotorasib vs 11.3 months for docetaxel; HR for OS between sotorasib and docetaxel: 1.01 [95% CI: 0.77, 1.33], p=0.53; Kaplan-Meier 12-month OS rate: 45.96% sotorasib, 46.49% docetaxel; indirect comparison: 39% reduction in risk of death [HR=0.611; 95% CI: 0.451, 0.829], median OS extension 7.2 months [15.3 vs 8.1 months]), progression-free survival (PFS; improvement of 1.1 months and 34% reduction in risk of progression or death [HR 0.66, 95% CI: 0.51, 0.86, p=0.002]; 12-month PFS: 24.8% sotorasib vs 10.1% docetaxel; subgroup analyses reported), objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event (AE) rate (measured by CTCAE v5), serious adverse events (Grade 3-4 AE rate), discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life; stable in sotorasib group, deterioration in docetaxel group; change in mean squared minimums from baseline to week 12 of 6.93 [95% CI: 3.66, 10.19]; delayed time to deterioration of overall health status [HR 0.694], delayed time to deterioration of physical functioning [HR 0.95]), time to deterioration of overall health status, time to deterioration of physical functioning"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "progression-free survival (PFS) (e.g., median 5.6 months [95% CI: 4.3; 7.8] in CodeBreaK 200; 6.7 months [95% CI: 4.6; 8.3] in Awad 2022; 6.1 months [95% CI: 5.6; not reached] in Julve 2021; with subgroup analyses by ECOG status and metastasis location), overall response rate (ORR) (e.g., 28% for sotorasib vs 13% for docetaxel; 21% in second-line population), disease control rate (DCR) (e.g., 83% for sotorasib vs docetaxel), overall survival (OS) (e.g., median 12.5 months [95% CI: 10.0; not achieved]), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires; includes assessment of symptoms such as pain, swelling, dyspnea, hair loss, chest bleeding, cough; higher functional score = deterioration, higher general health = improvement), adverse events (AEs) (including ≥ grade 3 AEs, treatment-related AEs, treatment-related AEs leading to discontinuation, treatment-related AEs resulting in death, serious adverse events [SAEs], and frequency of specific AEs such as diarrhoea, increased ALT/AST, fatigue, anaemia, constipation, neutropenia, fever, alopecia, etc.), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA], budget impact analysis from public payer perspective), time to progression on subsequent therapy, dose modification-related adverse drug reactions (ADRs), treatment discontinuation due to AEs, utilities (as part of cost-utility analysis), time to deterioration in quality of life"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), health status (measured by EQ-5D VAS), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    }
  }
}